Depósito Académico >
Facultad de Farmacia >
Departamento de Farmacia y Tecnología Farmacéutica >
DA - Farmacia - Tecnología Farmacéutica - Artículos de revista >
|Pharmacokinetic–pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats|
|Authors: ||Vasquez-Bahena, D.A. (D.A.)|
Salazar-Morales, U.E. (U.E.)
Ortiz, M.I. (M.I.)
Castañeda-Hernandez, G. (Gilberto)
Troconiz, I.F. (Iñaki F.)
|Keywords: ||Pharmacokinetic/pharmacodynamic modelling|
|Issue Date: ||2010|
|Publisher: ||British pharmacological society|
|Publisher version: ||http://dx.doi.org/10.1111/j.1476-5381.2009.00508.x|
|Citation: ||Vásquez-Bahena DA, Salazar-Morales UE, Ortiz MI, Castañeda-Hernández G, Trocóniz IF. Pharmacokinetic–pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats. Br J Pharmacol. 2010 Jan;159(1):176-87.|
|Background and purpose: This study establishes a pharmacokinetic/pharmacodynamic (PK/PD) model to describe the time course and in vivo mechanisms of action of the antinociceptive effects of lumiracoxib, evaluated by the thermal hyperalgesia test in rats. Experimental approach: Female Wistar fasted rats were injected s.c. with saline or carrageenan in the right hind paw, followed by either 0, 1, 3, 10 or 30 mg·kg-1 of oral lumiracoxib at the time of carrageenan injection (experiment I), or 0, 10 or 30 mg·kg-1 oral lumiracoxib at 4 h after carrageenan injection (experiment II). Antihyperalgesic responses were measured as latency time (LT) to a thermal stimulus. PK/PD modelling of the antinociceptive response was performed using the population approach with NONMEM VI.
Results: A two-compartment model described the plasma disposition. A first-order model, including lag time and decreased relative bioavailability as a function of the dose, described the absorption process. The response model was: LT = LT0/(1 + MED). LT0 is the baseline response, and MED represents the level of inflammatory mediators. The time course of MED was assumed to be equivalent to the predicted profile of COX-2 activity and was modelled according to an indirect response model with a time variant synthesis rate. Drug effects were described as a reversible inhibition of the COX-2 activity. The in vivo estimate of the dissociation equilibrium constant of the COX-2-lumiracoxib complex was 0.24 mg·mL-1.
Conclusions: The model developed appropriately described the time course of pharmacological responses to lumiracoxib, in terms of its mechanism of action and pharmacokinetics.|
|Permanent link: ||http://hdl.handle.net/10171/21706|
|Appears in Collections:||DA - Farmacia - Tecnología Farmacéutica - Artículos de revista|
|Files in This Item:|
| View / Open |
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.